133 related articles for article (PubMed ID: 12598776)
1. Significant levels of intracellular stavudine triphosphate are found in HIV-infected zidovudine-treated patients.
Becher F; Pruvost AG; Schlemmer DD; Créminon CA; Goujard CM; Delfraissy JF; Benech HC; Grassi JJ
AIDS; 2003 Mar; 17(4):555-61. PubMed ID: 12598776
[TBL] [Abstract][Full Text] [Related]
2. Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy.
Moore JD; Acosta EP; Johnson VA; Bassett R; Eron JJ; Fischl MA; Long MC; Kuritzkes DR; Sommadossi JP
Antivir Ther; 2007; 12(6):981-6. PubMed ID: 17926654
[TBL] [Abstract][Full Text] [Related]
3. Lack of evidence for in vivo transformation of zidovudine triphosphate to stavudine triphosphate in human immunodeficiency virus-infected patients.
Meléndez M; Blanco R; Delgado W; García R; Santana J; García H; Rosario O; Rodríguez JF
Antimicrob Agents Chemother; 2006 Mar; 50(3):835-40. PubMed ID: 16495240
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous quantitation of the 5'-triphosphate metabolites of zidovudine, lamivudine, and stavudine in peripheral mononuclear blood cells of HIV infected patients by high-performance liquid chromatography tandem mass spectrometry.
Moore JD; Valette G; Darque A; Zhou XJ; Sommadossi JP
J Am Soc Mass Spectrom; 2000 Dec; 11(12):1134-43. PubMed ID: 11118121
[TBL] [Abstract][Full Text] [Related]
5. Monitoring of didanosine and stavudine intracellular trisphosphorylated anabolite concentrations in HIV-infected patients.
Becher F; Landman R; Mboup S; Kane CN; Canestri A; Liegeois F; Vray M; Prevot MH; Leleu G; Benech H
AIDS; 2004 Jan; 18(2):181-7. PubMed ID: 15075534
[TBL] [Abstract][Full Text] [Related]
6. Relationship between HIV/Highly active antiretroviral therapy (HAART)-associated lipodystrophy syndrome and stavudine-triphosphate intracellular levels in patients with stavudine-based antiretroviral regimens.
Domingo P; Cabeza MC; Pruvost A; Salazar J; Gutierrez Mdel M; Mateo MG; Domingo JC; Fernandez I; Villarroya F; Muñoz J; Vidal F; Baiget M
Clin Infect Dis; 2010 Apr; 50(7):1033-40. PubMed ID: 20192724
[TBL] [Abstract][Full Text] [Related]
7. The prevalence of reduced zidovudine susceptibility in zidovudine-naive, antiretroviral-experienced HIV-1-infected patients.
Gilleece Y; Torti C; Mandalia S; Gazzard BG; Pillay D; Pozniak AL
HIV Med; 2003 Oct; 4(4):305-10. PubMed ID: 14525540
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of intracellular zidovudine and its phosphorylated anabolites in the absence and presence of stavudine using an in vitro human peripheral blood mononuclear cell (PBMC) model.
Brody SR; Aweeka FT
Int J Antimicrob Agents; 1997 Sep; 9(2):131-5. PubMed ID: 18611830
[TBL] [Abstract][Full Text] [Related]
9. Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens.
Jones SP; Qazi N; Morelese J; Lebrecht D; Sutinen J; Yki-Jărvinen H; Back DJ; Pirmohamed M; Gazzard BG; Walker UA; Moyle GJ
J Acquir Immune Defic Syndr; 2005 Dec; 40(5):565-72. PubMed ID: 16284533
[TBL] [Abstract][Full Text] [Related]
10. Influence of prior exposure to zidovudine on stavudine phosphorylation in vivo and ex vivo.
Hoggard PG; Sales SD; Phiboonbanakit D; Lloyd J; Maher BA; Khoo SH; Wilkins E; Carey P; Hart CA; Back DJ
Antimicrob Agents Chemother; 2001 Feb; 45(2):577-82. PubMed ID: 11158757
[TBL] [Abstract][Full Text] [Related]
11. An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine.
Foudraine NA; de Jong JJ; Jan Weverling G; van Benthem BH; Maas J; Keet IP; Jurriaans S; Roos MT; Vandermeulen K; de Wolf F; Lange JM
AIDS; 1998 Aug; 12(12):1513-9. PubMed ID: 9727573
[TBL] [Abstract][Full Text] [Related]
12. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
Squires KE; Gulick R; Tebas P; Santana J; Mulanovich V; Clark R; Yangco B; Marlowe SI; Wright D; Cohen C; Cooley T; Mauney J; Uffelman K; Schoellkopf N; Grosso R; Stevens M
AIDS; 2000 Jul; 14(11):1591-600. PubMed ID: 10983646
[TBL] [Abstract][Full Text] [Related]
13. Determination of zidovudine triphosphate intracellular concentrations in peripheral blood mononuclear cells from human immunodeficiency virus-infected individuals by tandem mass spectrometry.
Font E; Rosario O; Santana J; García H; Sommadossi JP; Rodriguez JF
Antimicrob Agents Chemother; 1999 Dec; 43(12):2964-8. PubMed ID: 10582890
[TBL] [Abstract][Full Text] [Related]
14. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
[TBL] [Abstract][Full Text] [Related]
15. Direct determination of phosphorylated intracellular anabolites of stavudine (d4T) by liquid chromatography/tandem mass spectrometry.
Pruvost A; Becher F; Bardouille P; Guerrero C; Creminon C; Delfraissy JF; Goujard C; Grassi J; Benech H
Rapid Commun Mass Spectrom; 2001; 15(16):1401-8. PubMed ID: 11507751
[TBL] [Abstract][Full Text] [Related]
16. Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators.
Kuritzkes DR; Marschner I; Johnson VA; Bassett R; Eron JJ; Fischl MA; Murphy RL; Fife K; Maenza J; Rosandich ME; Bell D; Wood K; Sommadossi JP; Pettinelli C
AIDS; 1999 Apr; 13(6):685-94. PubMed ID: 10397563
[TBL] [Abstract][Full Text] [Related]
17. Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults.
Anderson PL; Zheng JH; King T; Bushman LR; Predhomme J; Meditz A; Gerber J; Fletcher CV
AIDS; 2007 Sep; 21(14):1849-54. PubMed ID: 17721092
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic evaluation of the effects of ribavirin on zidovudine triphosphate formation: ACTG 5092s Study Team.
Aweeka FT; Kang M; Yu JY; Lizak P; Alston B; Chung RT;
HIV Med; 2007 Jul; 8(5):288-94. PubMed ID: 17561874
[TBL] [Abstract][Full Text] [Related]
19. Quantitation of zidovudine triphosphate concentrations from human peripheral blood mononuclear cells by anion exchange solid phase extraction and liquid chromatography-tandem mass spectroscopy; an indirect quantitation methodology.
King T; Bushman L; Anderson PL; Delahunty T; Ray M; Fletcher CV
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Feb; 831(1-2):248-57. PubMed ID: 16412710
[TBL] [Abstract][Full Text] [Related]
20. A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected children with virologic suppression.
Saez-Llorens X; Castaño E; Rathore M; Church J; Deville J; Gaur A; Estripeaut D; White K; Arterburn S; Enejosa JV; Cheng AK; Chuck SL; Rhee MS
Pediatr Infect Dis J; 2015 Apr; 34(4):376-82. PubMed ID: 25760565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
